This report was first published by Endpoints News. To see the original version, click here
Craig Crews has incubated some notable biotech companies this century, and hundreds of thousands of blood cancer patients have benefited from a medicine with roots in his Yale lab.
His lab’s discoveries, particularly in induced proximity and protein degradation, have spawned biotech companies such as Proteolix, Arvinas and Halda Therapeutics, which was bought last year by Johnson & Johnson for $3.05 billion. But while those were successes, the creation process was clunky — a series of one-off journeys with separate leadership teams.
您已阅读17%（627字），剩余83%（3095字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。